Toxicities of targeted therapies and their management in renal cancer: methodology of guidelines

被引：1
|
作者：
Escudier, Bernard [1 ]
Joly, Florence [2 ]
Soria, Jean-Charles [3 ]
机构：
[1] Inst Gustave Roussy, Dept Med, F-94805 Villejuif, France
[2] Ctr Francois Baclesse, F-14076 Caen 05, France
[3] Inst Gustave Roussy, SITEP, F-94805 Villejuif, France
来源：
BULLETIN DU CANCER | 2011年 / 98卷
关键词：
renal cell carcinoma; immunotherapy; nephrectomy; anti-angiogenesis; mammalian target of rapamycin; guidelines; toxicities; CELL CARCINOMA; INTERFERON-ALPHA; DOUBLE-BLIND; TEMSIROLIMUS; SUNITINIB;
D O I：
10.1684/bdc.2011.1444
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Advanced renal cell carcinoma (RCC) is associated with a poor prognosis and is refractory to standard chemotherapy. Recent progress in the understanding of molecular biology and pathogenesis of renal cell cancer has been translated into the development of new therapeutic strategies. The management of metastatic RCC has been revolutionized with the development of targeted molecular therapies against VEGF-VEGFR and mTOR. Randomized phase III clinical trials demonstrated clinical benefit for patients with advanced RCC in overall survival and progression free survival. Guidelines for the management of side effects induced by these targeted therapies seem to be warranted. Delta
引用
收藏
页码：S3 / S6
页数：4
相关论文
共 50 条
  • [41] Metastasis Targeted Therapies in Renal Cell Cancer
    Narter, K. Fehmi
    Ozveren, Bora
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2018, 17 (01): : 26 - 32
  • [42] Renal toxicity of targeted therapies
    Kelly, Ronan J.
    Billemont, Bertrand
    Rixe, Olivier
    TARGETED ONCOLOGY, 2009, 4 (02) : 121 - 133
  • [43] Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma
    Jose Mendez-Vidal, Maria
    Martinez Ortega, Esther
    Montesa Pino, Alvaro
    Perez Valderrama, Begona
    Viciana, Ruth
    CANCER AND METASTASIS REVIEWS, 2012, 31 : S19 - S27
  • [44] Advances in the Management of Metastatic Renal Cell Cancer
    Sternberg, Cora N.
    Bellmunt, Joaquim
    Gruenwald, Viktor
    Larkin, James
    Mulders, Peter
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (09) : 758 - 761
  • [45] Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population-based study
    Beisland, Christian
    Johannesen, Tom B.
    Klepp, Olbjorn
    Axcrona, Ulrika
    Torgersen, Knut Martin
    Kowalski, Jan
    Solli, Oddvar
    Sandin, Rickard
    Oldenburg, Jan
    ONCOTARGETS AND THERAPY, 2017, 10 : 371 - 385
  • [46] Side-effects of targeted therapies in the treatment of advanced renal cell carcinoma
    Kirchner, H.
    Merseburger, A. S.
    ONKOLOGE, 2011, 17 (02): : 155 - 162
  • [47] Selecting Targeted Therapies for Patients With Renal Cell Carcinoma
    Plimack, Elizabeth R.
    Hudes, Gary R.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2011, 9 (09): : 997 - 1007
  • [48] TARGETED THERAPY FOR METASTATIC RENAL CELL CANCER
    Verbaeys, C.
    Hoebeke, P.
    Van Belle, S.
    Rottey, S.
    ACTA CLINICA BELGICA, 2010, 65 (02) : 115 - 121
  • [49] Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer
    Gutierrez, Cristina
    McEvoy, Colleen
    Munshi, Laveena
    Stephens, R. Scott
    Detsky, Michael E.
    Nates, Joseph L.
    Pastores, Stephen M.
    CRITICAL CARE MEDICINE, 2020, 48 (01) : 10 - 21
  • [50] Sunitinib and other targeted therapies for renal cell carcinoma
    Powles, T.
    Chowdhury, S.
    Jones, R.
    Mantle, M.
    Nathan, P.
    Bex, A.
    Lim, L.
    Hutson, T.
    BRITISH JOURNAL OF CANCER, 2011, 104 (05) : 741 - 745
12345